The number of US adults living with heart failure has more than doubled over the past three decades, mostly due to the rising ...

The NY Center for the Prevention of Heart Disease announces expanded services for heart failure patients in Midtown Manhattan ...

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

Here are the top IVBM articles from 2025 capturing how value-based strategies are translating into real-world impact. Click ...

Cytokinetics has announced that the FDA has approved MYQORZO tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with oHCM .

Saint Joseph Health has announced the launch of a Community Paramedicine Program, the first hospital-based program of its kind in Lexington and one of only a few in Kentucky. This innovative program ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...

People struggling to pay for basic needs such as food, housing, and medical care face a sharply higher risk of death.

"People imagine a nurse quits after one traumatic night or a tragic patient death. That is not how it happens." ...